US7696320B2
(en)
*
|
2004-08-24 |
2010-04-13 |
Domantis Limited |
Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
|
US9321832B2
(en)
|
2002-06-28 |
2016-04-26 |
Domantis Limited |
Ligand
|
WO2004003144A2
(en)
|
2002-07-01 |
2004-01-08 |
Human Genome Sciences, Inc. |
Antibodies that specifically bind to reg iv
|
ATE414106T1
(de)
*
|
2003-06-30 |
2008-11-15 |
Domantis Ltd |
Pegylierte single-domain-antikörper (dab)
|
EP2322554A1
(en)
|
2004-06-30 |
2011-05-18 |
Domantis Limited |
Composition comprising an anti-TNF-alpha domain antibody for the treatment of rheumatoid arthritis
|
GB0521621D0
(en)
|
2005-10-24 |
2005-11-30 |
Domantis Ltd |
Tumor necrosis factor receptor 1 antagonists for treating respiratory diseases
|
JP2009504685A
(ja)
*
|
2005-08-15 |
2009-02-05 |
アラーナ・テラピューティクス・リミテッド |
新世界霊長類フレームワーク領域を用いる設計された抗体
|
KR20080077261A
(ko)
*
|
2005-12-06 |
2008-08-21 |
도만티스 리미티드 |
Egfr 및/또는 vegf에 대해 결합 특이성이 있는리간드 및 그의 사용 방법
|
US7981414B2
(en)
*
|
2005-12-20 |
2011-07-19 |
Cephalon Australia Pty Ltd |
Anti-inflammatory dAb
|
AU2007211829C9
(en)
*
|
2006-02-01 |
2013-07-11 |
Cephalon Australia Pty Ltd |
Domain antibody construct
|
WO2007117685A2
(en)
|
2006-04-07 |
2007-10-18 |
Nektar Therapeutics Al, Corporation |
Conjugates of an anti-tnf-alpha antibody
|
MX2009004027A
(es)
*
|
2006-10-20 |
2009-09-28 |
Schering Corp |
Anticuerpos anti factor de crecimiento endotelial vascular completamente humanos y metodos de uso.
|
US20080139790A1
(en)
*
|
2006-12-08 |
2008-06-12 |
Jennings Philip A |
Chimeric antibodies
|
EP2115004A2
(en)
|
2006-12-19 |
2009-11-11 |
Ablynx N.V. |
Amino acid sequences directed against gpcrs and polypeptides comprising the same for the treatment of gpcr-related diseases and disorders
|
EP2514767A1
(en)
|
2006-12-19 |
2012-10-24 |
Ablynx N.V. |
Amino acid sequences directed against a metalloproteinase from the ADAM family and polypeptides comprising the same for the treatment of ADAM-related diseases and disorders
|
US9512236B2
(en)
|
2006-12-19 |
2016-12-06 |
Ablynx N.V. |
Amino acid sequences directed against GPCRS and polypeptides comprising the same for the treatment of GPCR-related diseases and disorders
|
CN101663319A
(zh)
*
|
2007-02-21 |
2010-03-03 |
埃博灵克斯股份有限公司 |
针对血管内皮生长因子的氨基酸序列和包括其的多肽用于治疗特征在于过量和/或病理性血管发生或新血管形成的病症和疾病
|
CN101679511A
(zh)
*
|
2007-06-06 |
2010-03-24 |
杜门蒂斯有限公司 |
多肽、抗体可变域和拮抗剂
|
MX2009013137A
(es)
*
|
2007-06-06 |
2010-04-30 |
Domantis Ltd |
Metodos para seleccionar polipeptidos resistentes a la proteasa.
|
GB0724331D0
(en)
*
|
2007-12-13 |
2008-01-23 |
Domantis Ltd |
Compositions for pulmonary delivery
|
EP2173772A2
(en)
|
2007-07-03 |
2010-04-14 |
Ablynx N.V. |
Providing improved immunoglobulin sequences by mutating cdr and/or fr positions
|
WO2009030285A1
(en)
*
|
2007-09-07 |
2009-03-12 |
Ablynx N.V. |
Binding molecules with multiple binding sites, compositions comprising the same and uses thereof
|
US8975382B2
(en)
|
2007-11-27 |
2015-03-10 |
Ablynx N.V. |
Amino acid sequences directed against HER2 and polypeptides comprising the same for the treatment of cancers and/or tumors
|
US20110091462A1
(en)
|
2008-03-05 |
2011-04-21 |
Ablynx N.V. |
Novel antigen binding dimer-complexes, methods of making and uses thereof
|
CN102056945A
(zh)
|
2008-04-07 |
2011-05-11 |
埃博灵克斯股份有限公司 |
针对Notch途径的单可变结构域
|
CN102099378B
(zh)
|
2008-05-16 |
2016-01-20 |
埃博灵克斯股份有限公司 |
针对CXCR4和其他GPCRs的氨基酸序列以及包含所述氨基酸序列的多肽
|
SI2285408T1
(sl)
|
2008-06-05 |
2019-02-28 |
Ablynx N.V. |
Aminokislinska zaporedja usmerjena proti proteinom ovojnicam virusa in polipeptidi, ki zaporedja vsebujejo za zdravljenje virusnih bolezni
|
BRPI0914005A2
(pt)
*
|
2008-07-02 |
2015-11-17 |
Emergent Product Dev Seattle |
proteínas antagonistas tnf-alfa de ligação a alvos múltiplos
|
EP2352764B1
(en)
|
2008-10-14 |
2018-03-28 |
Ablynx N.V. |
AMINO ACID SEQUENCES TARGETING HUMAN CD4 and CXCR4, CCR5, TLR4, ALPHAV INTEGRIN, BETA3-INTEGRIN,BETA1-INTEGRIN, HUMAN ALPHA2-INTEGRIN, CD81, SR-BI, CLAUDIN-1, CLAUDIN-6 AND/OR CLAUDIN-9, RESPECTIVELY, AND NEUTRALIZING VIRAL ENTRY
|
US10118962B2
(en)
|
2008-10-29 |
2018-11-06 |
Ablynx N.V. |
Methods for purification of single domain antigen binding molecules
|
EP4104821A1
(en)
|
2008-10-29 |
2022-12-21 |
Ablynx N.V. |
Formulations of single domain antigen binding molecules
|
BRPI0921319A2
(pt)
*
|
2008-11-26 |
2018-10-16 |
Glaxo Group Ltd |
composição, método para dispensação de uma composição, e para tratar, prevenir ou diagnosticar uma condição ocular, e, processo para produzir uma composição farmacêutica
|
EP2364328A2
(en)
|
2008-12-10 |
2011-09-14 |
Ablynx NV |
Amino acid sequences directed against the angiopoietin/tie system and polypeptides comprising the same for the treatment of diseases and disorders related to angiogenesis
|
WO2010100135A1
(en)
|
2009-03-05 |
2010-09-10 |
Ablynx N.V. |
Novel antigen binding dimer-complexes, methods of making/avoiding and uses thereof
|
CA2758191C
(en)
|
2009-04-10 |
2015-06-30 |
Ablynx N.V. |
Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of il-6r related diseases and disorders
|
ES2864956T3
(es)
|
2009-04-30 |
2021-10-14 |
Ablynx Nv |
Procedimiento para la producción de anticuerpos de dominio
|
JP2012528112A
(ja)
*
|
2009-05-28 |
2012-11-12 |
グラクソ グループ リミテッド |
抗原結合タンパク質
|
ES2643034T3
(es)
|
2009-06-05 |
2017-11-21 |
Ablynx N.V. |
Construcciones de Nanobody contra el virus respiratorio sincicial humano (VRSH) trivalentes para la prevención y/o el tratamiento de infecciones de las vías respiratorias
|
HUE051430T2
(hu)
|
2009-07-10 |
2021-03-01 |
Ablynx Nv |
Eljárás variábilis domének elõállítására
|
PE20121647A1
(es)
|
2009-08-29 |
2012-12-31 |
Abbvie Inc |
Proteinas terapeuticas de union a dll4
|
PL3438126T3
(pl)
|
2009-09-03 |
2021-03-08 |
Ablynx N.V. |
Stabilne formulacje polipeptydów i ich zastosowanie
|
WO2011064382A1
(en)
|
2009-11-30 |
2011-06-03 |
Ablynx N.V. |
Improved amino acid sequences directed against human respiratory syncytial virus (hrsv) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections
|
WO2011073180A1
(en)
|
2009-12-14 |
2011-06-23 |
Ablynx N.V. |
Single variable domain antibodies against ox40l, constructs and therapeutic use
|
WO2011083141A2
(en)
|
2010-01-08 |
2011-07-14 |
Ablynx Nv |
Method for generation of immunoglobulin sequences by using lipoprotein particles
|
US9120855B2
(en)
|
2010-02-10 |
2015-09-01 |
Novartis Ag |
Biologic compounds directed against death receptor 5
|
CN105380904A
(zh)
|
2010-02-11 |
2016-03-09 |
埃博灵克斯股份有限公司 |
用于制备气雾剂的方法和组合物
|
RU2605928C2
(ru)
|
2010-03-02 |
2016-12-27 |
Эббви Инк. |
Терапевтические dll4-связывающие белки
|
US8937164B2
(en)
|
2010-03-26 |
2015-01-20 |
Ablynx N.V. |
Biological materials related to CXCR7
|
RU2012149227A
(ru)
|
2010-05-20 |
2014-06-27 |
Аблинкс Нв |
Биологические материалы, относящиеся к her3
|
WO2011161263A1
(en)
|
2010-06-25 |
2011-12-29 |
Ablynx Nv |
Pharmaceutical compositions for cutaneous administration
|
CN108314733A
(zh)
|
2010-07-16 |
2018-07-24 |
埃博灵克斯股份有限公司 |
修饰的单结构域抗原结合分子及其应用
|
BR112013002578A2
(pt)
|
2010-08-03 |
2019-05-14 |
Abbvie Inc. |
imunoglobinas de domínio variável duplo e usos das mesmas
|
CN103261222B
(zh)
|
2010-09-10 |
2017-07-28 |
医疗免疫有限公司 |
抗体衍生物
|
WO2012042026A1
(en)
|
2010-09-30 |
2012-04-05 |
Ablynx Nv |
Biological materials related to c-met
|
PL2632946T3
(pl)
|
2010-10-29 |
2018-06-29 |
Ablynx N.V. |
Sposób wytwarzania pojedynczych domen zmiennych immunoglobulin
|
CN103429620B
(zh)
|
2010-11-05 |
2018-03-06 |
酵活有限公司 |
在Fc结构域中具有突变的稳定异源二聚的抗体设计
|
EA202092589A3
(ru)
|
2010-11-08 |
2021-06-30 |
Аблинкс Н.В. |
Cxcr2-связывающие полипептиды
|
WO2012069557A1
(en)
*
|
2010-11-24 |
2012-05-31 |
Glaxo Group Limited |
Multispecific antigen binding proteins targeting hgf
|
US9468679B2
(en)
|
2011-03-28 |
2016-10-18 |
Ablynx N.V. |
Method for producing solid formulations comprising immunoglobulin single variable domains
|
CA2831415A1
(en)
|
2011-03-28 |
2012-10-04 |
Ablynx Nv |
Bispecific anti-cxcr7 immunoglobulin single variable domains
|
MX361242B
(es)
|
2011-03-30 |
2018-11-30 |
Ablynx Nv |
Anticuerpos de dominio sencillo contra tnf-alfa y usos de los mismos.
|
UA117218C2
(uk)
|
2011-05-05 |
2018-07-10 |
Мерк Патент Гмбх |
Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
|
EP3590950A1
(en)
|
2011-05-09 |
2020-01-08 |
Ablynx NV |
Method for the production of immunoglobulin single varible domains
|
US9505840B2
(en)
|
2011-05-27 |
2016-11-29 |
Ablynx N.V. |
Inhibition of bone resorption with RANKL binding peptides
|
JP2014525736A
(ja)
|
2011-06-23 |
2014-10-02 |
アブリンクス エン.ヴェー. |
IgEに対する免疫グロブリン単一可変ドメイン
|
KR101632620B1
(ko)
|
2011-07-27 |
2016-06-23 |
글락소 그룹 리미티드 |
Fc 도메인에 융합된 항vegf 단일 가변 도메인
|
EP2744828A4
(en)
*
|
2011-08-16 |
2014-12-31 |
Univ Emory |
JAML-SPECIFIC BINDING AGENTS, ANTIBODIES AND USES THEREOF
|
US10465005B2
(en)
|
2011-08-16 |
2019-11-05 |
Emory Patent Group |
JAML specific binding agents, antibodies, and uses related thereto
|
EP2987806A3
(en)
*
|
2011-08-17 |
2016-07-13 |
Glaxo Group Limited |
Modified single variable domain antibodies with reduced binding to anti-drug-antibodies
|
DK2747782T3
(en)
|
2011-09-23 |
2018-04-23 |
Ablynx Nv |
Long-term inhibition of interleukin-6-mediated signal transmission
|
WO2013045707A2
(en)
|
2011-09-30 |
2013-04-04 |
Ablynx Nv |
Biological materials related to c-met
|
KR102052774B1
(ko)
|
2011-11-04 |
2019-12-04 |
자임워크스 인코포레이티드 |
Fc 도메인 내의 돌연변이를 갖는 안정한 이종이합체 항체 설계
|
AU2013222414B2
(en)
|
2012-02-21 |
2018-02-15 |
Cytonics Corporation |
Systems, compositions, and methods for transplantation
|
AU2013258834B2
(en)
|
2012-05-10 |
2017-09-07 |
Zymeworks Bc Inc. |
Heteromultimer constructs of immunoglobulin heavy chains with mutations in the Fc domain
|
US11339208B1
(en)
|
2012-05-31 |
2022-05-24 |
United States Of America As Represented By The Secretary Of The Air Force |
Camelidae single-domain antibodies against Yersinia pestis and methods of use
|
WO2014004586A1
(en)
|
2012-06-25 |
2014-01-03 |
Zymeworks Inc. |
Process and methods for efficient manufacturing of highly pure asymmetric antibodies in mammalian cells
|
MY194330A
(en)
|
2012-11-01 |
2022-11-28 |
Abbvie Inc |
Anti-dll4/vegf dual variable domain immunoglobulin and uses thereof
|
US9914785B2
(en)
|
2012-11-28 |
2018-03-13 |
Zymeworks Inc. |
Engineered immunoglobulin heavy chain-light chain pairs and uses thereof
|
JP6388917B2
(ja)
|
2013-04-29 |
2018-09-12 |
アグロサーフエ・エン・フエー |
ポリペプチドからなる農薬組成物
|
WO2015031654A2
(en)
|
2013-08-28 |
2015-03-05 |
Cytonics Corporation |
Systems, compositions, and methods for transplantation and treating conditions
|
EP2883883A1
(en)
|
2013-12-16 |
2015-06-17 |
Cardio3 Biosciences S.A. |
Therapeutic targets and agents useful in treating ischemia reperfusion injury
|
NL2013007B1
(en)
|
2014-06-16 |
2016-07-05 |
Ablynx Nv |
Methods of treating TTP with immunoglobulin single variable domains and uses thereof.
|
NL2013661B1
(en)
|
2014-10-21 |
2016-10-05 |
Ablynx Nv |
KV1.3 Binding immunoglobulins.
|
JP2017538779A
(ja)
|
2014-10-10 |
2017-12-28 |
アブリンクス・エヌ・フェー |
Rsv感染の治療方法
|
KR102364212B1
(ko)
|
2014-10-10 |
2022-02-17 |
아블린쓰 엔.브이. |
호흡기 질병들의 에어로졸 치료에 사용하기 위한 흡입 디바이스
|
EP3215624B1
(en)
|
2014-11-05 |
2023-11-29 |
Biotalys NV |
Transgenic plant comprising a polynucleotide encoding a variable domain of heavy-chain antibody
|
US10093733B2
(en)
|
2014-12-11 |
2018-10-09 |
Abbvie Inc. |
LRP-8 binding dual variable domain immunoglobulin proteins
|
PT3233910T
(pt)
|
2014-12-19 |
2020-03-17 |
Ablynx Nv |
Dímeros de nanocorpos ligados a cisteína
|
JP6871866B2
(ja)
|
2015-02-03 |
2021-05-19 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
抗rho gtpaseコンホーメーションシングルドメイン抗体及びその使用
|
WO2016130451A1
(en)
*
|
2015-02-09 |
2016-08-18 |
Dnx Biotech, Llc |
Increasing the half-life of a full-length or a functional fragment of variant anti-human tnf-alpha antibody
|
WO2016135041A1
(en)
|
2015-02-26 |
2016-09-01 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Fusion proteins and antibodies comprising thereof for promoting apoptosis
|
CN107847559B
(zh)
|
2015-05-13 |
2022-07-01 |
埃博灵克斯股份有限公司 |
基于cd3反应性的t细胞募集多肽
|
ES2754427T3
(es)
|
2015-05-13 |
2020-04-17 |
Ablynx Nv |
Polipéptidos de reclutamiento de células T basados en la reactividad de TCR alfa/beta
|
TW201710286A
(zh)
|
2015-06-15 |
2017-03-16 |
艾伯維有限公司 |
抗vegf、pdgf及/或其受體之結合蛋白
|
CN105384825B
(zh)
|
2015-08-11 |
2018-06-01 |
南京传奇生物科技有限公司 |
一种基于单域抗体的双特异性嵌合抗原受体及其应用
|
US11078251B2
(en)
|
2015-09-18 |
2021-08-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
T cell receptors (TCR) and uses thereof for the diagnosis and treatment of diabetes
|
US10947598B2
(en)
|
2015-09-29 |
2021-03-16 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Methods for determining the metabolic status of lymphomas
|
EP3362088B1
(en)
|
2015-10-12 |
2020-11-25 |
Institut National de la Sante et de la Recherche Medicale (INSERM) |
An agent capable of depleting cd8 t cells for the treatment of myocardial infarction or acute myocardial infarction
|
EP3374389A1
(en)
|
2015-11-13 |
2018-09-19 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Anti- nkg2d single domain antibodies and uses thereof
|
RU2018122255A
(ru)
|
2015-11-27 |
2019-12-19 |
Аблинкс Нв |
Полипептиды, ингибирующие cd40l
|
US20200264165A1
(en)
|
2016-01-04 |
2020-08-20 |
Inserm (Institut National De La Sante Et De Larecherche Medicale) |
Use of pd-1 and tim-3 as a measure for cd8+ cells in predicting and treating renal cell carcinoma
|
WO2017129558A1
(en)
|
2016-01-25 |
2017-08-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for predicting or treating myelopoiesis-driven cardiometabolic diseases and sepsis
|
WO2017129763A1
(en)
|
2016-01-28 |
2017-08-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of signet ring cell gastric cancer
|
US10822415B2
(en)
|
2016-01-28 |
2020-11-03 |
Inserm (Institut National De La Santéet De La Recherche Médicale) |
Methods for enhancing the potency of the immune checkpoint inhibitors
|
WO2017129790A1
(en)
|
2016-01-28 |
2017-08-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical composition for the treatment of cancer
|
WO2017174681A1
(en)
|
2016-04-06 |
2017-10-12 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of age-related cardiometabolic diseases
|
WO2017182609A1
(en)
|
2016-04-22 |
2017-10-26 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical composition for the treatment of inflammatory skin diseases associated with desmoglein-1 deficiency
|
EP3452505A1
(en)
|
2016-05-02 |
2019-03-13 |
Ablynx NV |
Treatment of rsv infection
|
CN109310788A
(zh)
|
2016-05-03 |
2019-02-05 |
法国国家健康和医学研究院 |
Cd31shed作为分子靶标用于炎症成像
|
EP3452092B1
(en)
|
2016-05-06 |
2020-08-26 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Pharmaceutical compositions for the treatment of chemoresistant acute myeloid leukemia (aml)
|
US20190151346A1
(en)
|
2016-05-10 |
2019-05-23 |
INSERM (Institute National de la Santé et de la Recherche Médicale) |
Combinations therapies for the treatment of cancer
|
EP3463452A1
(en)
|
2016-05-24 |
2019-04-10 |
Institut National de la Sante et de la Recherche Medicale (INSERM) |
Methods and pharmaceutical compositions for the treatment of non small cell lung cancer (nsclc) that coexists with chronic obstructive pulmonary disease (copd)
|
WO2017202890A1
(en)
|
2016-05-27 |
2017-11-30 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for predicting and treating myeloma
|
PL3464318T3
(pl)
|
2016-06-02 |
2021-11-08 |
Abbvie Inc. |
Agonista receptora glukokortykoidowego i jego immunokoniugaty
|
WO2018007442A1
(en)
|
2016-07-06 |
2018-01-11 |
Ablynx N.V. |
Treatment of il-6r related diseases
|
WO2018014260A1
(en)
|
2016-07-20 |
2018-01-25 |
Nanjing Legend Biotech Co., Ltd. |
Multispecific antigen binding proteins and methods of use thereof
|
WO2018029182A1
(en)
|
2016-08-08 |
2018-02-15 |
Ablynx N.V. |
Il-6r single variable domain antibodies for treatment of il-6r related diseases
|
WO2018041989A1
(en)
|
2016-09-02 |
2018-03-08 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for diagnosing and treating refractory celiac disease type 2
|
EP3510407A1
(en)
|
2016-09-08 |
2019-07-17 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for diagnosing and treating nephrotic syndrome
|
US11098113B2
(en)
|
2016-09-15 |
2021-08-24 |
Vib Vzw |
Immunoglobulin single variable domains directed against macrophage migration inhibitory factor
|
WO2018068201A1
(en)
|
2016-10-11 |
2018-04-19 |
Nanjing Legend Biotech Co., Ltd. |
Single-domain antibodies and variants thereof against ctla-4
|
WO2018087391A1
(en)
|
2016-11-14 |
2018-05-17 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for modulating stem cells proliferation or differentiation
|
JP7222888B2
(ja)
|
2016-11-16 |
2023-02-15 |
アブリンクス エン.ヴェー. |
Cd123及びtcrアルファ/ベータに結合することが可能なt細胞動員ポリペプチド
|
US20210277145A1
(en)
|
2016-11-17 |
2021-09-09 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Methods and pharmaceutical compositions for increasing endogenous protein level
|
WO2018099968A1
(en)
|
2016-11-29 |
2018-06-07 |
Ablynx N.V. |
Treatment of infection by respiratory syncytial virus (rsv)
|
EP3548894B1
(en)
|
2016-12-02 |
2021-10-20 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for diagnosing renal cell carcinoma
|
WO2018134389A1
(en)
|
2017-01-23 |
2018-07-26 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating infections
|
US11471538B2
(en)
|
2017-02-10 |
2022-10-18 |
INSERM (Institut National de la Santéet de la Recherche Medicale) |
Methods and pharmaceutical compositions for the treatment of cancers associated with activation of the MAPK pathway
|
CA3054623A1
(en)
|
2017-02-28 |
2018-09-07 |
Vib Vzw |
Means and methods for oral protein delivery
|
WO2018172508A1
(en)
|
2017-03-24 |
2018-09-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating melanoma
|
WO2018178029A1
(en)
|
2017-03-27 |
2018-10-04 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating degenerative muscular and/or neurological conditions or diseases
|
WO2018178030A1
(en)
|
2017-03-27 |
2018-10-04 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating degenerative muscular and/or neurological conditions or diseases
|
EP3601325B1
(en)
|
2017-03-28 |
2023-07-19 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
New tau species
|
WO2018178237A1
(en)
|
2017-03-30 |
2018-10-04 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the treatment of mitochondrial genetic diseases
|
CA3062238A1
(en)
|
2017-05-11 |
2018-11-15 |
Vib Vzw |
Glycosylation of variable immunoglobulin domains
|
US20200171022A1
(en)
|
2017-05-17 |
2020-06-04 |
Inserm (Institut National De La Santé Et Da La Recherche Médicale) |
Flt3 inhibitors for improving pain treatments by opioids
|
US20200190216A1
(en)
|
2017-06-02 |
2020-06-18 |
Merck Patent Gmbh |
Mmp13 binding immunoglobulins
|
TWI826376B
(zh)
|
2017-06-02 |
2023-12-21 |
德商麥克專利有限公司 |
與adamts5、mmp13及聚集蛋白聚醣結合的多肽
|
EP3630847A1
(en)
|
2017-06-02 |
2020-04-08 |
Merck Patent GmbH |
Adamts binding immunoglobulins
|
AU2018277310A1
(en)
|
2017-06-02 |
2019-12-12 |
Ablynx Nv |
Aggrecan binding immunoglobulins
|
EP3634582A1
(en)
|
2017-06-08 |
2020-04-15 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating hyperpigmentation disorders
|
US20200096507A1
(en)
|
2017-06-08 |
2020-03-26 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Chimeric receptor for use in whole-cell sensors for detecting analytes of interest
|
EP3641802A1
(en)
|
2017-06-22 |
2020-04-29 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of fibrosis with agents capable of inhibiting the activation of mucosal-associated invariant t (mait) cells
|
WO2019000223A1
(en)
|
2017-06-27 |
2019-01-03 |
Nanjing Legend Biotech Co., Ltd. |
ENABLERS OF IMMUNE EFFECTOR CELLS OF CHIMERIC ANTIBODIES AND METHODS OF USE THEREOF
|
WO2019002548A1
(en)
|
2017-06-29 |
2019-01-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
TREATMENT OF MIGRAINE WITH TREK1, TREK2 AGONIZATION OR HETEROMERS COMPRISING SAME
|
US11155607B2
(en)
|
2017-07-19 |
2021-10-26 |
Vib Vzw |
Serum albumin binding agents
|
WO2019016310A1
(en)
|
2017-07-20 |
2019-01-24 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
METHODS AND COMPOSITIONS FOR TREATING CANCERS
|
US11174322B2
(en)
|
2017-07-24 |
2021-11-16 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Antibodies and peptides to treat HCMV related diseases
|
US11926664B2
(en)
|
2017-07-25 |
2024-03-12 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for modulating monocytopoiesis
|
US20200197547A1
(en)
|
2017-08-30 |
2020-06-25 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Anti-mesothelin radiolabelled single domain antibodies suitable for the imaging and treatment of cancers
|
EP3457139A1
(en)
|
2017-09-19 |
2019-03-20 |
Promise Advanced Proteomics |
Antibody-like peptides for quantifying therapeutic antibodies
|
CN111655340A
(zh)
|
2017-09-20 |
2020-09-11 |
国家医疗保健研究所 |
用于调节自噬的方法和药物组合物
|
WO2019086548A1
(en)
|
2017-10-31 |
2019-05-09 |
Vib Vzw |
Novel antigen-binding chimeric proteins and methods and uses thereof
|
MA50893A
(fr)
|
2017-11-15 |
2020-09-23 |
Novo Nordisk As |
Liants de facteur x renforçant l'activation fx
|
WO2019101995A1
(en)
|
2017-11-27 |
2019-05-31 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for cardiac regeneration
|
US10772970B2
(en)
|
2017-12-01 |
2020-09-15 |
Abbvie Inc. |
Glucocorticoid receptor agonist and immunoconjugates thereof
|
AU2018396970A1
(en)
|
2017-12-28 |
2020-08-13 |
Nanjing Legend Biotech Co., Ltd. |
Single-domain antibodies and variants thereof against TIGIT
|
US20210072244A1
(en)
|
2018-01-04 |
2021-03-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating melanoma resistant
|
EP3740507A4
(en)
|
2018-01-15 |
2022-08-24 |
Nanjing Legend Biotech Co., Ltd. |
SINGLE DOMAIN ANTIBODIES AND VARIANTS THEREOF AGAINST PD-1
|
US20210054064A1
(en)
|
2018-01-24 |
2021-02-25 |
INSERM (Institut National de la Santé et de la Recherche Médicale |
Antagonists of il-33 for use in methods for preventing ischemia reperfusion injusry in an organ
|
SG11202006902QA
(en)
|
2018-02-06 |
2020-08-28 |
Ablynx Nv |
Methods of treating initial episode of ttp with immunoglobulin single variable domains
|
JP7384811B2
(ja)
|
2018-02-16 |
2023-11-21 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
白斑を処置するための方法及び組成物
|
EP3758742A1
(en)
|
2018-03-01 |
2021-01-06 |
Vrije Universiteit Brussel |
Human pd-l1-binding immunoglobulins
|
CN116942851A
(zh)
|
2018-03-23 |
2023-10-27 |
布鲁塞尔自由大学 |
Wnt信号传递激动剂分子
|
EP3774917A4
(en)
|
2018-03-30 |
2022-01-19 |
Nanjing Legend Biotech Co., Ltd. |
SINGLE DOMAIN ANTIBODIES AGAINST LAG-3 AND USES THEREOF
|
WO2019193375A1
(en)
|
2018-04-04 |
2019-10-10 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of fzd7 inhibitors for the treatment of retinal neovascularization
|
WO2019207030A1
(en)
|
2018-04-26 |
2019-10-31 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for predicting a response with an immune checkpoint inhibitor in a patient suffering from a lung cancer
|
EP3846909A1
(en)
|
2018-09-05 |
2021-07-14 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Methods and compositions for treating asthma and allergic diseases
|
EP3850008A1
(en)
|
2018-09-10 |
2021-07-21 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of an inhibitor of ntsr1 activation or expression for preventing weight loss, muscle loss, and protein blood level decrease in subjects in need thereof
|
US20220047567A1
(en)
|
2018-09-10 |
2022-02-17 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the treatment of neurofibromatosis
|
EP3852740A1
(en)
|
2018-09-17 |
2021-07-28 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Use of inhibitors of phosphatase activity of soluble epoxide for the treatment of cardiometabolic diseases
|
JP2022511337A
(ja)
|
2018-09-19 |
2022-01-31 |
インサーム (インスティテュート ナショナル デ ラ サンテ エ デ ラ ルシェルシェ メディカル) |
免疫チェックポイント治療に抵抗性のある癌の治療のための方法および医薬組成物
|
EP3856772A1
(en)
|
2018-09-25 |
2021-08-04 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Use of antagonists of th17 cytokines for the treatment of bronchial remodeling in patients suffering from allergic asthma
|
WO2020070062A1
(en)
|
2018-10-01 |
2020-04-09 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of tim-3 inhibitors for the treatment of exacerbations in patients suffering from severe asthma
|
US20210340278A1
(en)
|
2018-10-04 |
2021-11-04 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical composition for the treatment of mucosal inflammatory diseases
|
US20210355216A1
(en)
|
2018-10-05 |
2021-11-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale |
Methods and systems for controlling the agonistic properties of antibody variable domains by light
|
EP3636657A1
(en)
|
2018-10-08 |
2020-04-15 |
Ablynx N.V. |
Chromatography-free antibody purification method
|
US20210347898A1
(en)
|
2018-10-09 |
2021-11-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of alpha-v-integrin (cd51) inhibitors for the treatment of cardiac fibrosis
|
WO2020079162A1
(en)
|
2018-10-18 |
2020-04-23 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for inducing full ablation of hematopoiesis
|
GB201818460D0
(en)
*
|
2018-11-13 |
2018-12-26 |
Crescendo Biologics Ltd |
Single domain antibodies that bind human serum albumin
|
WO2020104479A1
(en)
|
2018-11-20 |
2020-05-28 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating cancers and resistant cancers with anti transferrin receptor 1 antibodies
|
WO2020115261A1
(en)
|
2018-12-07 |
2020-06-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating melanoma
|
WO2020120592A1
(en)
|
2018-12-12 |
2020-06-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for predicting and treating melanoma
|
WO2020120644A1
(en)
|
2018-12-13 |
2020-06-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
New anti tau svqivykpv epitope single domain antibody
|
WO2020127885A1
(en)
|
2018-12-21 |
2020-06-25 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Compositions for treating cancers and resistant cancers
|
AU2020205150A1
(en)
|
2019-01-03 |
2021-07-22 |
Assistance Publique-Hôpitaux De Paris (Aphp) |
Methods and pharmaceutical compositions for enhancing CD8+ T cell-dependent immune responses in subjects suffering from cancer
|
EP3921031A1
(en)
|
2019-02-04 |
2021-12-15 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Methods and compositions for modulating blood-brain barrier
|
WO2020169707A1
(en)
|
2019-02-21 |
2020-08-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Foxo1 inhibitor for use in the treatment of latent virus infection
|
EP3935391B1
(en)
|
2019-03-05 |
2024-04-24 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Biomarkers for renal cell carcinoma
|
US20220143204A1
(en)
|
2019-03-08 |
2022-05-12 |
Linxis B.V. |
Internalizing binding molecules targeting receptors involved in cell proliferation or in cell differentiation
|
WO2020193520A1
(en)
|
2019-03-25 |
2020-10-01 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Treatment of taupathy disorders by targeting new tau species
|
US20220249511A1
(en)
|
2019-03-29 |
2022-08-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the treatment of keloid, hypertrophic scars and/or hyperpigmentation disorders
|
WO2020201362A2
(en)
|
2019-04-02 |
2020-10-08 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods of predicting and preventing cancer in patients having premalignant lesions
|
WO2020201442A1
(en)
|
2019-04-03 |
2020-10-08 |
Orega Biotech |
Combination therapies based on pd1 and il-17b inhibitors
|
US20220220565A1
(en)
|
2019-04-30 |
2022-07-14 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating melanoma
|
US20220228116A1
(en)
|
2019-05-28 |
2022-07-21 |
Vib Vzw |
Cd8+ t-cells lacking plexins and their application in cancer treatment
|
US20220220197A1
(en)
|
2019-05-28 |
2022-07-14 |
Vib Vzw |
Cancer Treatment by Targeting Plexins in the Immune Compartment
|
US20220259295A1
(en)
|
2019-06-20 |
2022-08-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method useful in tolerance induction therapy and kits therefore
|
WO2021023644A1
(en)
|
2019-08-02 |
2021-02-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Neutralizing granzyme b for providing cardioprotection in a subject who experienced a myocardial infarction
|
WO2021048292A1
(en)
|
2019-09-11 |
2021-03-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating melanoma
|
WO2021063968A1
(en)
|
2019-09-30 |
2021-04-08 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method and composition for diagnosing chronic obstructive pulmonary disease
|
US20220354811A1
(en)
|
2019-10-03 |
2022-11-10 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for modulating macrophages polarization
|
EP4037710A1
(en)
|
2019-10-04 |
2022-08-10 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Methods and pharmaceutical composition for the treatment of ovarian cancer, breast cancer or pancreatic cancer
|
WO2021078359A1
(en)
|
2019-10-21 |
2021-04-29 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of inhibitors of cubilin for the treatment of chronic kidney diseases
|
JP2023500954A
(ja)
|
2019-11-12 |
2023-01-11 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
潜伏形態のトキソプラズマ症についての新たな血清マーカー
|
GB201918279D0
(en)
|
2019-12-12 |
2020-01-29 |
Vib Vzw |
Glycosylated single chain immunoglobulin domains
|
US20230076415A1
(en)
|
2020-01-17 |
2023-03-09 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating melanoma
|
WO2021170750A1
(en)
|
2020-02-28 |
2021-09-02 |
Orega Biotech |
Combination therapies based on ctla4 and il-17b inhibitors
|
CN115915939A
(zh)
|
2020-03-31 |
2023-04-04 |
生物催化公司 |
抗真菌多肽
|
WO2021198511A1
(en)
|
2020-04-03 |
2021-10-07 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treatment of sars-cov-2 infection
|
JP2023523600A
(ja)
|
2020-04-22 |
2023-06-06 |
マブウェル (シャンハイ) バイオサイエンス カンパニー リミテッド |
ヒトプログラム細胞死リガンド1(pd-l1)を標的とする単一可変ドメイン抗体およびその誘導体
|
WO2021224401A1
(en)
|
2020-05-07 |
2021-11-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for determining a reference range of β-galactose exposure platelet
|
EP4149558A1
(en)
|
2020-05-12 |
2023-03-22 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
New method to treat cutaneous t-cell lymphomas and tfh derived lymphomas
|
WO2021229104A1
(en)
|
2020-05-15 |
2021-11-18 |
Université de Liège |
Anti-cd38 single-domain antibodies in disease monitoring and treatment
|
EP4153627A1
(en)
|
2020-05-20 |
2023-03-29 |
Institut Curie |
Synthetic single domain library
|
CA3182333A1
(en)
|
2020-05-20 |
2021-11-25 |
Institut Curie |
Single domain antibodies and their use in cancer therapies
|
US20230235326A1
(en)
|
2020-06-05 |
2023-07-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for treating ocular diseases
|
JP2023530919A
(ja)
|
2020-06-17 |
2023-07-20 |
ヤンセン バイオテツク,インコーポレーテツド |
多能性幹細胞の製造のための材料及び方法
|
EP4153636A1
(en)
|
2020-06-29 |
2023-03-29 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Anti-protein s single-domain antibodies and polypeptides comprising thereof
|
WO2022008597A1
(en)
|
2020-07-08 |
2022-01-13 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical composition for the treatment of infectious diseases
|
JP2023535610A
(ja)
|
2020-07-28 |
2023-08-18 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
ガンを予防及び処置するための方法及び組成物
|
US20230323299A1
(en)
|
2020-08-03 |
2023-10-12 |
Inserm (Institut National De La Santé Et De La Recherch Médicale) |
Population of treg cells functionally committed to exert a regulatory activity and their use for adoptive therapy
|
JP2023541934A
(ja)
|
2020-09-16 |
2023-10-04 |
リンクシス ベスローテン フェンノートシャップ |
内在化結合分子
|
WO2022063957A1
(en)
|
2020-09-24 |
2022-03-31 |
Vib Vzw |
Biomarker for anti-tumor therapy
|
CA3196737A1
(en)
|
2020-09-24 |
2022-03-31 |
Massimiliano Mazzone |
Combination of p2y6 inhibitors and immune checkpoint inhibitors
|
WO2022064049A1
(en)
|
2020-09-28 |
2022-03-31 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method for diagnosing brucella infection
|
WO2022079270A1
(en)
|
2020-10-16 |
2022-04-21 |
Université D'aix-Marseille |
Anti-gpc4 single domain antibodies
|
WO2022084300A1
(en)
|
2020-10-20 |
2022-04-28 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for diagnosis and monitoring form of coronavirus infection
|
WO2022084531A1
(en)
|
2020-10-23 |
2022-04-28 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating glioma
|
WO2022096547A1
(en)
|
2020-11-05 |
2022-05-12 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of il-6 inhibitors for the treatment of acute chest syndrome in patients suffering from sickle cell disease
|
WO2022101481A1
(en)
|
2020-11-16 |
2022-05-19 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for predicting and treating uveal melanoma
|
EP4256067A2
(en)
|
2020-12-04 |
2023-10-11 |
Tidal Therapeutics, Inc. |
Ionizable cationic lipids and lipid nanoparticles, and methods of synthesis and use thereof
|
TW202222840A
(zh)
|
2020-12-11 |
2022-06-16 |
大陸商上海華奧泰生物藥業股份有限公司 |
Cd73的抗原結合蛋白及其應用
|
CN117062908A
(zh)
|
2021-01-11 |
2023-11-14 |
星济生物(苏州)有限公司 |
靶向金黄色葡萄球菌α-毒素的抗原结合蛋白及其应用
|
JP2024502758A
(ja)
|
2021-01-13 |
2024-01-23 |
上海華奥泰生物藥業股▲フン▼有限公司 |
Cd73結合タンパク質及びその使用
|
EP4277934A1
(en)
|
2021-01-14 |
2023-11-22 |
Institut Curie |
Her2 single domain antibodies variants and cars thereof
|
CN116963773A
(zh)
|
2021-01-21 |
2023-10-27 |
浙江养生堂天然药物研究所有限公司 |
治疗肿瘤的组合物及方法
|
EP4294407A1
(en)
|
2021-02-17 |
2023-12-27 |
Vib Vzw |
Inhibition of slc4a4 in the treatment of cancer
|
CN117321076A
(zh)
|
2021-02-19 |
2023-12-29 |
美国卫生及公众服务部代表 |
中和SARS-CoV-2的单结构域抗体
|
BR112023016713A2
(pt)
|
2021-02-19 |
2023-10-31 |
Seoul Nat Univ R&Db Foundation |
Anticorpo ou um fragmento de ligação ao antígeno do mesmo, molécula de ácido nucleico, métodos para produzir um anticorpo ou um fragmento de ligação ao antígeno do mesmo e para detectar agrupamento de diferenciação 47 ou determinar uma quantidade de agrupamento de diferenciação 47 em uma amostra, e, uso do anticorpo ou de um fragmento de ligação ao antígeno do mesmo
|
EP4296284A1
(en)
|
2021-02-19 |
2023-12-27 |
SHAPERON Inc. |
Bispecific single domain antibody to pd-l1 and cd47 and use thereof
|
KR20220118962A
(ko)
|
2021-02-19 |
2022-08-26 |
(주)샤페론 |
Pd-l1에 대한 단일 도메인 항체 및 이의 용도
|
WO2022194908A1
(en)
|
2021-03-17 |
2022-09-22 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating melanoma
|
WO2022199527A1
(zh)
|
2021-03-22 |
2022-09-29 |
星济生物(苏州)有限公司 |
靶向肺炎链球菌溶血素的抗原结合蛋白及其用途
|
WO2022200303A1
(en)
|
2021-03-23 |
2022-09-29 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the diagnosis and treatment of t cell-lymphomas
|
EP4299593A1
(en)
|
2021-04-02 |
2024-01-03 |
Oricell Therapeutics Co., Ltd. |
Cldn18.2 antigen-binding protein and use thereof
|
WO2022214681A1
(en)
|
2021-04-09 |
2022-10-13 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the treatment of anaplastic large cell lymphoma
|
WO2022223488A1
(en)
|
2021-04-19 |
2022-10-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of splice switching oligonucleotides for exon skipping-mediated knockdown of pim2
|
WO2022223791A1
(en)
|
2021-04-23 |
2022-10-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating cell senescence accumulation related disease
|
WO2022242892A1
(en)
|
2021-05-17 |
2022-11-24 |
Université de Liège |
Anti-cd38 single-domain antibodies in disease monitoring and treatment
|
US20230174651A1
(en)
|
2021-06-23 |
2023-06-08 |
Janssen Biotech, Inc. |
Materials and methods for hinge regions in functional exogenous receptors
|
IL309559A
(en)
|
2021-07-09 |
2024-02-01 |
Luxembourg Inst Of Health Lih |
Dimeric protein complexes and their uses
|
WO2023285362A1
(en)
|
2021-07-12 |
2023-01-19 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of il-36 inhibitors for the treatment of netherton syndrome
|
WO2023006975A2
(en)
|
2021-07-30 |
2023-02-02 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Chimeric proteins and methods of immunotherapy
|
WO2023057601A1
(en)
|
2021-10-06 |
2023-04-13 |
Biotalys NV |
Anti-fungal polypeptides
|
WO2023078900A1
(en)
|
2021-11-03 |
2023-05-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating triple negative breast cancer (tnbc)
|
WO2023110937A1
(en)
|
2021-12-14 |
2023-06-22 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Depletion of nk cells for the treatment of adverse post-ischemic cardiac remodeling
|
WO2023118165A1
(en)
|
2021-12-21 |
2023-06-29 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating melanoma
|
EP4209508A1
(en)
|
2022-01-11 |
2023-07-12 |
Centre national de la recherche scientifique |
Nanobodies for the deneddylating enzyme nedp1
|
WO2023144235A1
(en)
|
2022-01-27 |
2023-08-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for monitoring and treating warburg effect in patients with pi3k-related disorders
|
WO2023144303A1
(en)
|
2022-01-31 |
2023-08-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Cd38 as a biomarker and biotarget in t-cell lymphomas
|
EP4231017A1
(en)
|
2022-02-17 |
2023-08-23 |
Promise Proteomics |
Detection and quantification of anti-drug antibodies and anti-self antibodies
|
EP4257609A1
(en)
|
2022-04-08 |
2023-10-11 |
iOmx Therapeutics AG |
Combination therapies based on pd-1 inhibitors and sik3 inhibitors
|
WO2023198648A1
(en)
|
2022-04-11 |
2023-10-19 |
Institut National de la Santé et de la Recherche Médicale |
Methods for the diagnosis and treatment of t-cell malignancies
|
WO2023198851A1
(en)
|
2022-04-14 |
2023-10-19 |
Institut National de la Santé et de la Recherche Médicale |
Methods for controlling the tumor cell killing by light
|
WO2023198874A1
(en)
|
2022-04-15 |
2023-10-19 |
Institut National de la Santé et de la Recherche Médicale |
Methods for the diagnosis and treatment of t cell-lymphomas
|
WO2023217904A1
(en)
|
2022-05-10 |
2023-11-16 |
Institut National de la Santé et de la Recherche Médicale |
Syncitin-1 fusion proteins and uses thereof for cargo delivery into target cells
|
US20240002331A1
(en)
|
2022-06-08 |
2024-01-04 |
Tidal Therapeutics, Inc. |
Ionizable cationic lipids and lipid nanoparticles, and methods of synthesis and use thereof
|
WO2023237661A1
(en)
|
2022-06-09 |
2023-12-14 |
Institut National de la Santé et de la Recherche Médicale |
Use of endothelin receptor type b agonists for the treatment of aortic valve stenosis
|
WO2024003310A1
(en)
|
2022-06-30 |
2024-01-04 |
Institut National de la Santé et de la Recherche Médicale |
Methods for the diagnosis and treatment of acute lymphoblastic leukemia
|
EP4299124A1
(en)
|
2022-06-30 |
2024-01-03 |
Universite De Montpellier |
Anti-mglur2 nanobodies for use as biomolecule transporter
|
WO2024008274A1
(en)
|
2022-07-04 |
2024-01-11 |
Universiteit Antwerpen |
T regulatory cell modification
|
WO2024008755A1
(en)
|
2022-07-04 |
2024-01-11 |
Vib Vzw |
Blood-cerebrospinal fluid barrier crossing antibodies
|
WO2024008799A1
(en)
|
2022-07-06 |
2024-01-11 |
Institut National de la Santé et de la Recherche Médicale |
Methods for the treatment of proliferative glomerulonephritis
|
WO2024013234A1
(en)
|
2022-07-13 |
2024-01-18 |
Institut National de la Santé et de la Recherche Médicale |
Methods for diagnosis, prognosis, stratification and treating of myocarditis
|
WO2024018003A1
(en)
|
2022-07-21 |
2024-01-25 |
Institut National de la Santé et de la Recherche Médicale |
Extracellular vesicles functionalized with an erv syncitin and uses thereof for cargo delivery
|
WO2024018046A1
(en)
|
2022-07-22 |
2024-01-25 |
Institut National de la Santé et de la Recherche Médicale |
Garp as a biomarker and biotarget in t-cell malignancies
|
WO2024018426A1
(en)
|
2022-07-22 |
2024-01-25 |
Janssen Biotech, Inc. |
Enhanced transfer of genetic instructions to effector immune cells
|
WO2024023283A1
(en)
|
2022-07-29 |
2024-02-01 |
Institut National de la Santé et de la Recherche Médicale |
Lrrc33 as a biomarker and biotarget in cutaneous t-cell lymphomas
|
WO2024028433A1
(en)
|
2022-08-04 |
2024-02-08 |
Institut National de la Santé et de la Recherche Médicale |
Methods for the treatment of lymphoproliferative disorders
|
WO2024033399A1
(en)
|
2022-08-10 |
2024-02-15 |
Institut National de la Santé et de la Recherche Médicale |
Sigmar1 ligand for the treatment of pancreatic cancer
|
WO2024033400A1
(en)
|
2022-08-10 |
2024-02-15 |
Institut National de la Santé et de la Recherche Médicale |
Sk2 inhibitor for the treatment of pancreatic cancer
|
WO2024038112A1
(en)
|
2022-08-17 |
2024-02-22 |
Institut National de la Santé et de la Recherche Médicale |
Improved anti-albumin nanobodies and their uses
|
WO2024047110A1
(en)
|
2022-08-31 |
2024-03-07 |
Institut National de la Santé et de la Recherche Médicale |
Method to generate more efficient car-t cells
|
WO2024074713A1
(en)
|
2022-10-07 |
2024-04-11 |
Institut National de la Santé et de la Recherche Médicale |
Method to generate improving car-t cells
|
WO2024079192A1
(en)
|
2022-10-12 |
2024-04-18 |
Institut National de la Santé et de la Recherche Médicale |
Cd81 as a biomarker and biotarget in t-cell malignancies
|
WO2024083843A1
(en)
|
2022-10-18 |
2024-04-25 |
Confo Therapeutics N.V. |
Amino acid sequences directed against the melanocortin 4 receptor and polypeptides comprising the same for the treatment of mc4r-related diseases and disorders
|
WO2024084034A1
(en)
|
2022-10-21 |
2024-04-25 |
Institut National de la Santé et de la Recherche Médicale |
Methods and pharmaceutical compositions for the treatment of osteoarthritis
|